Apixaban 2.5 mg BID; Standard-dose DOAC
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07575867/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 464 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 04.2032.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 24
Критерии включения
- Age ≥18 years;
- Documented nonvalvular AF (≥30 seconds on ECG within previous 12 months);
- CHA2DS2-VASc score ≥3 for women and ≥2 for men;
- Signed informed consent to participate in the study;
Критерии невключения
- Active indication for anticoagulation OTHER than atrial fibrillation at the time of enrollment and/or the predicted/unpredicted occurrence of such indications during the entire study period (e.g., mechanical valve, acute VTE, recent PE requiring >3 months anticoagulation);
- Inability to tolerate at least 3 months of apixaban therapy (for LAAC arm);
- Indications for antiplatelet therapy or therapy with P2Y12 inhibitors at the time of inclusion and/or the predicted/unpredicted occurrence of such indications during the entire study period;
- The presence of mechanical prosthetic heart valves, mitral stenosis of severe or moderate degree;
- Active DVT requiring anticoagulation;
- Congenital or acquired haemostasis disorders, rheumatic heart disease or recurrent deep vein thrombosis;
- Left ventricular ejection fraction (LVEF) < 30%;
- Glomerular filtration rate (GFR) < 30 ml/min (stage IV or V chronic kidney disease) or dialysis patient;
- Severe liver failure, including cirrhosis and Child-Pugh Class C/D;
- NYHA class IV congestive heart failure;
- The patient had a myocardial infarction - MI with or without ST segment elevation (STEMI, NSTEMI) with or without intervention, within 30 days before LAAC;
- The patient had a stroke (of any cause, ischemic or hemorrhagic) within 30 days before LAAC;
- Intracardiac thrombus before LAAC;
- Major bleeding according to BARC criteria (type 3 and higher) within 30 days before LAAC or before randomization;
- Amyloid cardiomyopathy;
- Platelet count < 100,000 x 109/l;
- The patient participates in another study, with the exception of observational studies without therapeutic interventions;
- Pregnant or breast-feeding patients, patients planning pregnancy during the study period;
- The LAAC procedure was unsuccessful or interrupted for technical reasons;
- PDL (peridevice leak) ≥ 3 mm;
- Contraindications for one of the treatment regimens prescribed by the study protocol (including allergic reactions);
- Planned cardiac or non-cardiac surgical procedure within 30 days before or 90 days after LAAC. Minor procedures not requiring discontinuation of antithrombotic therapy are permitted (e.g., cardioversion, catheter ablation, cataract surgery);
- The patient has a heart tumor, active infection, signs of physiological tamponade;
- The documented life expectancy of the patient is less than 12 months;
Источник: ClinicalTrials.gov, NCT07575867 · запись обновлена в реестре 8 мая 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 6
- Composite of major adverse events — 36 months from enrollment
Цель исследования
This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation. Left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation for preventing cardioembolic events in patients with atrial fibrillation. However, the optimal post-procedural antithrombotic regimen following LAAC remains unclear, with no consensus on evidence-based therapy. Given current trends in cardiology favoring reduced-intensity antithrombotic strategies, this study aims to contribute to the evidence base by evaluating whether LAAC followed by reduced-dose apixaban (2.5 mg BID) for 3 months with subsequent complete withdrawal of antithrombotic therapy is superior to long-term standard-dose DOAC therapy in patients with non-valvular atrial fibrillation.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07575867 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.